Table 2 Dsg2 expression level and CC patients’ clinicopathological characteristics
From: DSG2 expression is low in colon cancer and correlates with poor survival
Characteristics | n | Dsg2 | Pearson X2 | P-value | |
|---|---|---|---|---|---|
Low and no | High | ||||
Total | 587 | 330 (56.22%) | 257 (43.78%) | Â | Â |
Gender | Â | Â | Â | 0.54 | 0.463 |
 Male | 351 | 193 (54.99%) | 158 (45.01%) |  |  |
 Female | 236 | 137 (58.05%) | 99 (41.95%) |  |  |
Age | Â | Â | Â | 0.79 | 0.376 |
 < 60 | 215 | 126 (58.60%) | 89 (41.40%) |  |  |
 ≥ 60 | 372 | 204 (54.84%) | 168 (45.16%) |  |  |
Location | Â | Â | Â | 3.02 | 0.389 |
 Right | 188 | 110 (58.51%) | 78 (41.49%) |  |  |
 Transverse | 77 | 46 (59.74%) | 31 (40.26%) |  |  |
 Left | 114 | 67 (58.77%) | 47 (41.23%) |  |  |
 Sigmoid | 208 | 107 (51.44%) | 101 (48.56%) |  |  |
Histological type | Â | Â | Â | 0.42 | 0.515 |
 Adenocarcinoma | 522 | 291 (55.75%) | 231 (44.25%) |  |  |
 Mucinous/SRCCa | 65 | 39 (60.00%) | 26 (40.00%) |  |  |
Differentiation | Â | Â | Â | 8.77 | 0.033* |
 Well | 156 | 83 (53.21%) | 73 (46.95%) |  |  |
 Moderate | 314 | 173 (55.10%) | 141 (44.91%) |  |  |
 Poor | 99 | 58 (58.59%) | 41 (41.41%) |  |  |
 Othersb | 18 | 16 (88.89%) | 2 (11.11%) |  |  |
Tumor size | Â | Â | Â | 1.44 | 0.696 |
 T1 | 42 | 25 (59.52%) | 17 (40.48%) |  |  |
 T2 | 61 | 37 (60.66%) | 24 (39.34%) |  |  |
 T3 | 200 | 115 (57.50%) | 85 (42.50%) |  |  |
 T4 | 284 | 153 (53.87%) | 131 (46.13%) |  |  |
Lymph node metastasis | Â | Â | Â | 6.21 | 0.045* |
 N0 | 328 | 171 (52.13%) | 157 (47.87%) |  |  |
 N1 | 168 | 99 (58.93%) | 69 (41.07%) |  |  |
 N2 | 91 | 60 (65.93%) | 31 (34.07%) |  |  |
Distant metastasis | Â | Â | Â | 7.90 | 0.005* |
 M0 | 495 | 266 (53.74%) | 229 (46.26%) |  |  |
 M1 | 92 | 64 (69.57%) | 28 (30.43%) |  |  |
AJCC stage |  |  |  | 18.54 |  < 0.001* |
 I | 63 | 28 (44.44%) | 35 (55.56%) |  |  |
 II | 199 | 95 (47.74%) | 104 (52.26%) |  |  |
 III | 233 | 143 (61.37%) | 90 (38.63%) |  |  |
 IV | 92 | 64 (69.57%) | 28 (30.43%) |  |  |
Venous invasion | Â | Â | Â | 0.15 | 0.697 |
 Negative | 501 | 280 (55.89%) | 221 (44.11%) |  |  |
 Positive | 86 | 50 (58.14%) | 36 (41.86%) |  |  |
Perineural invasion | Â | Â | Â | 0.24 | 0.623 |
 Negative | 507 | 283 (55.82%) | 224 (44.18%) |  |  |
 Positive | 80 | 47 (58.75%) | 33 (41.25%) |  |  |
Preoperative CEA, ng/ml | Â | Â | Â | 1.17 | 0.557 |
 ≤ 5 | 259 | 150 (57.92%) | 109 (42.08%) |  |  |
 > 5 | 285 | 154 (54.04%) | 131 (45.96%) |  |  |
 Unknown | 43 | 26 (60.47%) | 17 (39.53%) |  |  |
Preoperative CA199, ng/ml | Â | Â | Â | 1.06 | 0.588 |
 ≤ 37 | 261 | 151 (57.85%) | 110 (42.15%) |  |  |
 > 37 | 281 | 152 (54.09%) | 129 (45.91%) |  |  |
 Unknown | 45 | 27 (60.00%) | 18 (40.00%) |  |  |
Ki67 | Â | Â | Â | 0.58 | 0.444 |
 Negative | 181 | 106 (58.56%) | 75 (41.44%) |  |  |
 Positive | 406 | 224 (55.17%) | 182 (44.83%) |  |  |